var data={"title":"Defibrotide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Defibrotide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/44082?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=defibrotide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Defibrotide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=defibrotide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Defibrotide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46387167\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Defitelio</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214047\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiplatelet Agent;</li>\n      <li>\n        Thrombolytic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214094\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Utilize baseline body weight (prior to the preparative hematopoietic stem cell transplantation regimen) to calculate the defibrotide dose. Ensure that patients are hemodynamically stable (on no more than 1 vasopressor agent) and are not experiencing clinically significant bleeding prior to defibrotide administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), treatment: </b> IV: 6.25 mg/kg every 6 hours for at least 21 days and up to a maximum of 60 days (until SOS resolution or hospital discharge) (Richardson 2016) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214093\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=defibrotide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Defibrotide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Utilize baseline body weight (prior to the preparative hematopoietic stem cell transplantation regimen) to calculate the defibrotide dose. Ensure that patients are hemodynamically stable (on no more than 1 vasopressor agent) and are not experiencing clinically significant bleeding prior to defibrotide administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), treatment:</b> Infants &gt;1 month, Children, and Adolescents: IV: 6.25 mg/kg every 6 hours for at least 21 days and up to a maximum of 60 days (until SOS resolution or hospital discharge) (Richardson 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic sinusoidal obstruction syndrome (SOS; formerly called VOD), prevention (off-label use): </b> Infants &gt;1 month, Children, and Adolescents: IV: 6.25 mg/kg every 6 hours beginning the same day as the conditioning regimen and continuing for at least 14 and up to 30 days post-transplant (Corbacioglu 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214095\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46420412\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Defibrotide is not removed by hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46420413\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46420414\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bleeding:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Persistent, severe or potentially life-threatening:</i> Withhold defibrotide; treat underlying cause of bleeding and provide supportive care. Consider reinitiating treatment (at the same dose and volume) when bleeding has resolved and the patient is hemodynamically stable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Recurrent significant bleeding:</i> Discontinue permanently (do not resume).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity reactions, severe or life-threatening (eg, anaphylaxis):</b> Discontinue permanently (do not resume).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Invasive procedures: </b>Discontinue defibrotide at least 2 hours prior to procedure. May resume treatment post-procedure once any risk of bleeding (related to procedure) is resolved.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46387168\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Defitelio: 200 mg/2.5 mL (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214046\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46233143\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Defitelio: FDA approved March 2016; anticipated availability is currently unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214096\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 2 hours using a 0.2 micron in-line filter. Flush the IV line with D5W or NS immediately before and after administration. Do not administer with other medications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46229946\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Hepatic sinusoidal obstruction syndrome (treatment): </b>Treatment of hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) with renal or pulmonary dysfunction following hematopoietic stem cell transplant (HSCT). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475161\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hepatic sinusoidal obstruction syndrome (prevention) (pediatrics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214042\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Defibrotide may be confused with dofetilide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Defitelio may be confused with dofetilide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214062\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (11% to 37%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (24%), vomiting (18%), nausea (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (59%; any type)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Intracranial hemorrhage (3%), cerebral hemorrhage (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperuricemia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Pulmonary hemorrhage (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Graft versus host disease (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (7%), infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary alveolar hemorrhage (7% to 9%), pulmonary infiltrates (6%), pneumonia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, abdominal pain, bloody diarrhea, hematemesis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Oral hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46420406\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to defibrotide or any component of the formulation; concomitant administration with systemic anticoagulant or fibrinolytic therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214051\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Defibrotide may increase the risk of bleeding (based on increased activity of fibrinolytic enzymes <i>in vitro</i>). Do not initiate therapy in patients with active bleeding; monitor closely for signs of bleeding. If bleeding develops while on therapy, discontinue defibrotide, evaluate/treat the underlying cause, and provide supportive care until bleeding resolves.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (eg, rash, urticaria, and angioedema) have been reported (rare). One patient with a history of previous defibrotide exposure experienced an anaphylactic reaction. Monitor closely for hypersensitivity reactions, particularly in patients who have received defibrotide previously. Discontinue therapy for severe hypersensitivity reactions and treat accordingly; monitor until symptoms resolve.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Exclusion criteria: Predominant exclusion criteria from phase III studies were preexisting liver cirrhosis, prior solid organ transplant, dialysis dependence (at the time of transplant), oxygen dependence during conditioning, clinically significant bleeding, and hemodynamic instability (&gt;1 pressor agent to maintain blood pressure) (Richardson 2011; Richardson 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulants/fibrinolytics: Concomitant use with systemic anticoagulant or fibrinolytic therapy is contraindicated; may increase the risk of bleeding (not including agents [anticoagulant or fibrinolytic] used to maintain or clear central lines). Discontinue anticoagulants and fibrinolytic medications prior to initiating defibrotide; consider delaying defibrotide until anticoagulant effects have subsided. Patients were excluded from studies if on concurrent medication which increased the risk of hemorrhage (except heparin flushes when used for central line management or dialysis) (Richardson 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Invasive procedures: There is no known reversal agent for defibrotide. Discontinue infusion at least 2 hours prior to an invasive procedure; may resume infusion post-procedure once the risk of procedure-related bleeding is resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porcine derived: Defibrotide is derived from porcine tissue. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46361050\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46361047\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83451&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Thrombolytic Agents may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with thrombolytic agents prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46420404\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46420405\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if defibrotide is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214098\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs and symptoms of hepatic SOS and hypersensitivity reactions; monitor for bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214071\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Defibrotide augments plasmin enzymatic activity to hydrolyze fibrin clots. It reduces endothelial cell (EC) activation and increases EC-mediated fibrinolysis by increasing tissue plasminogen activator and thrombomodulin expression, as well as by decreasing von Willebrand factor and plasminogen activator inhibitor-1 expression.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14214073\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 8.1 to 9.1 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 93% to human plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Polynucleotides are metabolized via nucleases, nucleotidases, nucleosidases, deaminases, and phosphorylases to oligonucleotides, nucleotides, nucleosides, and then to the free 2&rsquo;-deoxyribose sugar, purine and pyrimidine bases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: &lt;2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (5% to 15% of total dose)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46817089\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Defitelio Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/2.5 mL (2.5 mL): $1,019.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059504\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Defitelio (AT, CZ, DE, DK, EE, FI, GB, HR, HU, IE, IL, LT, MT, NL, NO, PL, PT, RO, SE, SI, SK);</li>\n      <li>Noravid (GR);</li>\n      <li>Novarid (IT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Benimetskaya L, Wu S, Voskresenskiy AM, et al, &ldquo;Angiogenesis Alteration by Defibrotide: Implications for its Mechanism of Action in Severe Hepatic Veno-Occlusive Disease,&rdquo; <i>Blood</i>, 2008, 112(10):4343-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/18711003/pubmed\" target=\"_blank\" id=\"18711003\">18711003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22364685\"></a>Corbacioglu S, Cesaro S, Faraci M, et al, &ldquo;Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Paediatric Haemopoietic Stem-Cell Transplantation: An Open-Label, Phase 3, Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2012, 379(9823):1301-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/22364685/pubmed\" target=\"_blank\" id=\"22364685\">22364685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Defitelio (defibrotide) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Defitelio (defibrotide) [summary product characteristics]. Villa Guardia, Italy: Gentium SpA; March 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/14661036/pubmed\" target=\"_blank\" id=\"14661036\">14661036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmer KJ and Goa KL, &ldquo;Defibrotide: a Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Vascular Disorders,&rdquo; <i>Drugs</i>, 1993, 45(2):259-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/7681375/pubmed\" target=\"_blank\" id=\"7681375\">7681375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i>. 2016;127(13):1656-1665.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/26825712/pubmed\" target=\"_blank\" id=\"26825712\">26825712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Smith AR, Grupp, SA, et al, &ldquo;Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol,&rdquo; <i>Blood</i>, 2011, 118(21):487 [abstract #487 from 2011 ASH Annual Meeting]</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Soiffer RJ, Antin JH, et al, &ldquo;Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure After Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2010, 16(7):1005-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/20167278/pubmed\" target=\"_blank\" id=\"20167278\">20167278</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83451 Version 61.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46387167\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14214047\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14214094\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F14214093\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14214095\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46420412\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46420413\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F46420414\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46387168\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14214046\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46233143\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14214096\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46229946\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475161\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14214042\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14214062\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46420406\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14214051\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46361050\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46361047\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46420404\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46420405\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14214098\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14214071\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14214073\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46817089\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059504\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/83451|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=defibrotide-patient-drug-information\" class=\"drug drug_patient\">Defibrotide: Patient drug information</a></li><li><a href=\"topic.htm?path=defibrotide-pediatric-drug-information\" class=\"drug drug_pediatric\">Defibrotide: Pediatric drug information</a></li></ul></div></div>","javascript":null}